Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phase III regenerative medicine trial for heart failure cleared to start

This article was originally published in Clinica

Executive Summary

A Phase III trial of a regenerative medicine for heart failure, highlighted in Clinica recently, has been cleared to start by Belgian regulators. Cardio3 BioSciences' Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European trial for C3BS-CQR-1, an autologous stem cell therapy for heart failure, which the firm gave details of in August, can now begin (www.clinica.co.uk, 20 August 2012).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel